Meiwu Technology Company Limited (“WNW” or the “Company”), (NASDAQ: WNW) announced today that on February 27, 2025, the ...

Last month, another Chinese beverage maker Guming, advised by Skadden, Shihui Partners and Ogier, also listed and raised $230 ...

ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial ...

China's central bank, together with other top financial regulators, convened a high-level symposium on Friday to discuss ...

China's central bank and financial regulators held a meeting with private enterprises and financial institutions, vowing to ...

The U.S. Securities and Exchange Commission (SEC) has recently changed its overall approach to crypto-related enforcement ...

About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Officials and economist said specific measures to be taken this year include incentivising State-owned capital investment in ...

China is expected to further ramp up reforms to bolster the country’s financial strength this year, a move of critical ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...